Apnimed is positioning an IPO to fund the commercial launch of an obstructive sleep apnea therapy that is awaiting an FDA decision. The update ties financing expectations directly to an FDA outcome and suggests the company plans to scale after approval. The company’s stated path—pending regulatory action followed by launch readiness—puts investor attention on FDA timing and any label or post-market requirements that could affect commercialization. For sleep and respiratory biotech investors, the deal dynamic is that approval could unlock a funding-then-launch cycle, while delays can extend burn and shift market expectations for the asset’s timetable.